TRANSMEDICS GROUP INC (TMDX) Fundamental Analysis & Valuation

NASDAQ:TMDX • US89377M1099

121.31 USD
-7.66 (-5.94%)
Last: Mar 12, 2026, 03:56 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TMDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to TMDX. TMDX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. TMDX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. TMDX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes TMDX very considerable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. TMDX Profitability Analysis

1.1 Basic Checks

  • TMDX had positive earnings in the past year.
  • In the past year TMDX had a positive cash flow from operations.
  • In multiple years TMDX reported negative net income over the last 5 years.
  • In multiple years TMDX reported negative operating cash flow during the last 5 years.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • TMDX has a better Return On Assets (17.81%) than 97.83% of its industry peers.
  • The Return On Equity of TMDX (40.22%) is better than 98.91% of its industry peers.
  • The Return On Invested Capital of TMDX (8.76%) is better than 85.87% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for TMDX is below the industry average of 9.15%.
  • The 3 year average ROIC (4.27%) for TMDX is below the current ROIC(8.76%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROIC 8.76%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 300 400

1.3 Margins

  • TMDX has a Profit Margin of 31.43%. This is amongst the best in the industry. TMDX outperforms 98.91% of its industry peers.
  • With an excellent Operating Margin value of 17.93%, TMDX belongs to the best of the industry, outperforming 88.59% of the companies in the same industry.
  • TMDX has a Gross Margin of 59.92%. This is in the better half of the industry: TMDX outperforms 61.41% of its industry peers.
  • In the last couple of years the Gross Margin of TMDX has declined.
Industry RankSector Rank
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TMDX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TMDX is destroying value.
  • The number of shares outstanding for TMDX has been increased compared to 1 year ago.
  • TMDX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, TMDX has an improved debt to assets ratio.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • TMDX has an Altman-Z score of 5.61. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
  • TMDX has a Altman-Z score of 5.61. This is amongst the best in the industry. TMDX outperforms 81.52% of its industry peers.
  • The Debt to FCF ratio of TMDX is 3.84, which is a good value as it means it would take TMDX, 3.84 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.84, TMDX belongs to the best of the industry, outperforming 80.43% of the companies in the same industry.
  • A Debt/Equity ratio of 1.06 is on the high side and indicates that TMDX has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.06, TMDX is not doing good in the industry: 76.09% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Altman-Z 5.61
ROIC/WACC0.92
WACC9.51%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 7.14 indicates that TMDX has no problem at all paying its short term obligations.
  • TMDX's Current ratio of 7.14 is amongst the best of the industry. TMDX outperforms 86.41% of its industry peers.
  • TMDX has a Quick Ratio of 6.59. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
  • TMDX's Quick ratio of 6.59 is amongst the best of the industry. TMDX outperforms 88.04% of its industry peers.
Industry RankSector Rank
Current Ratio 7.14
Quick Ratio 6.59
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TMDX Growth Analysis

3.1 Past

  • TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 178.22%, which is quite impressive.
  • TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.13%.
  • TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 88.21% yearly.
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%

3.2 Future

  • TMDX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.03% yearly.
  • The Revenue is expected to grow by 17.79% on average over the next years. This is quite good.
EPS Next Y-6.95%
EPS Next 2Y15.67%
EPS Next 3Y18.54%
EPS Next 5Y12.03%
Revenue Next Year22.69%
Revenue Next 2Y20.67%
Revenue Next 3Y18.6%
Revenue Next 5Y17.79%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. TMDX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 43.17, the valuation of TMDX can be described as expensive.
  • Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than the industry average as 68.48% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.15. TMDX is valued rather expensively when compared to this.
  • With a Price/Forward Earnings ratio of 46.40, TMDX can be considered very expensive at the moment.
  • 66.85% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
  • TMDX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.27.
Industry RankSector Rank
PE 43.17
Fwd PE 46.4
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than 67.39% of the companies in the same industry.
  • TMDX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 77.17% of the companies in the same industry.
Industry RankSector Rank
P/FCF 31.15
EV/EBITDA 32.76
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The decent profitability rating of TMDX may justify a higher PE ratio.
  • TMDX's earnings are expected to grow with 18.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.67%
EPS Next 3Y18.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TMDX Dividend Analysis

5.1 Amount

  • No dividends for TMDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TMDX Fundamentals: All Metrics, Ratios and Statistics

TRANSMEDICS GROUP INC

NASDAQ:TMDX (3/12/2026, 3:56:50 PM)

121.31

-7.66 (-5.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners111.11%
Inst Owner Change-1.75%
Ins Owners2.99%
Ins Owner Change1.41%
Market Cap4.16B
Revenue(TTM)605.49M
Net Income(TTM)190.29M
Analysts83
Price Target148.92 (22.76%)
Short Float %24.77%
Short Ratio10.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.66%
Min EPS beat(2)32.92%
Max EPS beat(2)84.39%
EPS beat(4)4
Avg EPS beat(4)96.18%
Min EPS beat(4)32.92%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)170.32%
EPS beat(12)10
Avg EPS beat(12)118.73%
EPS beat(16)13
Avg EPS beat(16)92.69%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)1.22%
Revenue beat(4)3
Avg Revenue beat(4)4.11%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)5.48%
Revenue beat(12)10
Avg Revenue beat(12)10.09%
Revenue beat(16)14
Avg Revenue beat(16)16.58%
PT rev (1m)0%
PT rev (3m)1.1%
EPS NQ rev (1m)-6.58%
EPS NQ rev (3m)-5.48%
EPS NY rev (1m)-11.51%
EPS NY rev (3m)-10.81%
Revenue NQ rev (1m)1.51%
Revenue NQ rev (3m)1.51%
Revenue NY rev (1m)1.77%
Revenue NY rev (3m)1.79%
Valuation
Industry RankSector Rank
PE 43.17
Fwd PE 46.4
P/S 6.87
P/FCF 31.15
P/OCF 21.58
P/B 8.8
P/tB 9.05
EV/EBITDA 32.76
EPS(TTM)2.81
EY2.32%
EPS(NY)2.61
Fwd EY2.16%
FCF(TTM)3.89
FCFY3.21%
OCF(TTM)5.62
OCFY4.63%
SpS17.65
BVpS13.79
TBVpS13.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.53
Profitability
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROCE 11.09%
ROIC 8.76%
ROICexc 17.48%
ROICexgc 17.98%
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
FCFM 22.06%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
ROICexc(3y)8.3%
ROICexc(5y)N/A
ROICexgc(3y)8.55%
ROICexgc(5y)N/A
ROCE(3y)5.4%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Debt/EBITDA 3.7
Cap/Depr 217.96%
Cap/Sales 9.79%
Interest Coverage 10.15
Cash Conversion 142.04%
Profit Quality 70.2%
Current Ratio 7.14
Quick Ratio 6.59
Altman-Z 5.61
F-Score7
WACC9.51%
ROIC/WACC0.92
Cap/Depr(3y)910.54%
Cap/Depr(5y)653.45%
Cap/Sales(3y)34%
Cap/Sales(5y)25.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
EPS Next Y-6.95%
EPS Next 2Y15.67%
EPS Next 3Y18.54%
EPS Next 5Y12.03%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%
Revenue Next Year22.69%
Revenue Next 2Y20.67%
Revenue Next 3Y18.6%
Revenue Next 5Y17.79%
EBIT growth 1Y189.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.48%
EBIT Next 3Y45.75%
EBIT Next 5Y46.88%
FCF growth 1Y265.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y295.14%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSMEDICS GROUP INC / TMDX FAQ

Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to TMDX.


Can you provide the valuation status for TRANSMEDICS GROUP INC?

ChartMill assigns a valuation rating of 4 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.


How profitable is TRANSMEDICS GROUP INC (TMDX) stock?

TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 6 / 10.


How financially healthy is TRANSMEDICS GROUP INC?

The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.